Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. III) If sequential tarlatamab and radiation is not deemed safe, we would allow for continued enrollment to assess efficacy of drug sans radiation treatment, enriching for tumors not of small cell lung cancer histology and allowing for patients without sites amenable to RT. A nested phase II study will attempt to assess for ORR and safety of study intervention amongst tumors not of small cell lung cancer histology.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony histologicznie nawracający lub oporny na leczenie rak płuc drobnokomórkowy (SCLC) lub inne nowotwory neuroendokrynne
- •Obecność białka DLL3 w komórkach nowotworu (co najmniej 1% dodatniość)
- •Wcześniejsze leczenie - choroba postępująca mimo co najmniej jednej linii terapii
- •Stan zdrowia ogólny 0-2 w skali ECOG (pacjent może wykonywać zwykłe czynności)
- •Spodziewana długość życia co najmniej 12 tygodni
- •Dostępne próbki tkanki nowotworu lub zgodność na pobranie biopsji
- •Możliwość zmierzenia zmian nowotworowych w badaniach obrazowych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Arizona Cancer Center at UMC North/University Medical Center
Tucson, United States
University of Washington Fred Hutchinson Cancer Center
Seattle, United States
Trial contact
Rachel E Jarrett, MPH
Michele Chu, MS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.